CN102365275B - 羧酰胺化合物及其使用方法 - Google Patents

羧酰胺化合物及其使用方法 Download PDF

Info

Publication number
CN102365275B
CN102365275B CN201080015415.6A CN201080015415A CN102365275B CN 102365275 B CN102365275 B CN 102365275B CN 201080015415 A CN201080015415 A CN 201080015415A CN 102365275 B CN102365275 B CN 102365275B
Authority
CN
China
Prior art keywords
hydrocarbyl
compound according
independently selected
halogen
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080015415.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102365275A (zh
Inventor
I.S.达维什
鸿辉
R.辛格
徐香
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of CN102365275A publication Critical patent/CN102365275A/zh
Application granted granted Critical
Publication of CN102365275B publication Critical patent/CN102365275B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N61/00—Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201080015415.6A 2009-01-28 2010-01-28 羧酰胺化合物及其使用方法 Expired - Fee Related CN102365275B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14798209P 2009-01-28 2009-01-28
US61/147,982 2009-01-28
PCT/US2010/022411 WO2010088392A1 (en) 2009-01-28 2010-01-28 Carboxamide compounds and methods for using the same

Publications (2)

Publication Number Publication Date
CN102365275A CN102365275A (zh) 2012-02-29
CN102365275B true CN102365275B (zh) 2014-09-24

Family

ID=42061132

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080015415.6A Expired - Fee Related CN102365275B (zh) 2009-01-28 2010-01-28 羧酰胺化合物及其使用方法

Country Status (17)

Country Link
US (2) US8362235B2 (cg-RX-API-DMAC7.html)
EP (1) EP2391616B1 (cg-RX-API-DMAC7.html)
JP (1) JP5658688B2 (cg-RX-API-DMAC7.html)
KR (1) KR101693061B1 (cg-RX-API-DMAC7.html)
CN (1) CN102365275B (cg-RX-API-DMAC7.html)
AU (1) AU2010208247B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1007287B8 (cg-RX-API-DMAC7.html)
CA (1) CA2750835C (cg-RX-API-DMAC7.html)
EA (1) EA022083B1 (cg-RX-API-DMAC7.html)
ES (1) ES2581678T3 (cg-RX-API-DMAC7.html)
IL (1) IL214203A (cg-RX-API-DMAC7.html)
MX (1) MX2011007639A (cg-RX-API-DMAC7.html)
NZ (1) NZ594556A (cg-RX-API-DMAC7.html)
SG (1) SG172974A1 (cg-RX-API-DMAC7.html)
UA (1) UA106600C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010088392A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201105215B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132136A1 (en) 2008-04-23 2009-10-29 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
US8796254B2 (en) 2010-03-31 2014-08-05 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds
HUE052110T2 (hu) 2010-07-29 2021-04-28 Rigel Pharmaceuticals Inc AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk
US9005909B2 (en) 2011-01-06 2015-04-14 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring AMPK activation
US9409884B2 (en) 2012-02-01 2016-08-09 Rigel Pharmaceuticals, Inc. 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ampkを活性化させるインダゾール化合物
US20150087673A1 (en) * 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
US20160214967A1 (en) 2013-09-30 2016-07-28 The University Of Tokyo Activator of adiponectin receptor
EP3737361A4 (en) 2018-01-11 2021-08-25 Centaurus Therapeutics INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR THE TREATMENT OF DISEASES
US12194023B2 (en) 2018-11-29 2025-01-14 The Research Foundation For The State University Of New York Compositions and methods for modular control of bioorthogonal ligation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1305472A (zh) * 1998-05-13 2001-07-25 株式会社同和药品工业 新的2,5-吡啶二羧酸衍生物
WO2008083124A1 (en) * 2006-12-28 2008-07-10 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
AU2001287898A1 (en) * 2000-09-22 2002-04-02 Stephen Garland Pyrazolopyridines and pyrazolopyridazines as antidiabetics
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
CA2634235A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
DE602006021591D1 (de) 2006-12-11 2011-06-09 Genetics Co Inc Aromatische 1,4-DI-Carboxylamide und deren Verwendung
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
EP2231600B1 (en) 2007-11-16 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
EP2231666B1 (en) * 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
WO2009132136A1 (en) * 2008-04-23 2009-10-29 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
US8796254B2 (en) 2010-03-31 2014-08-05 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1305472A (zh) * 1998-05-13 2001-07-25 株式会社同和药品工业 新的2,5-吡啶二羧酸衍生物
WO2008083124A1 (en) * 2006-12-28 2008-07-10 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use

Also Published As

Publication number Publication date
SG172974A1 (en) 2011-08-29
ES2581678T3 (es) 2016-09-06
US20130131078A1 (en) 2013-05-23
KR20110119755A (ko) 2011-11-02
US8362235B2 (en) 2013-01-29
EA201170979A1 (ru) 2012-02-28
EP2391616A1 (en) 2011-12-07
IL214203A (en) 2015-01-29
CA2750835C (en) 2018-09-04
HK1164860A1 (zh) 2012-09-28
NZ594556A (en) 2013-11-29
CA2750835A1 (en) 2010-08-05
IL214203A0 (en) 2011-08-31
ZA201105215B (en) 2012-09-26
CN102365275A (zh) 2012-02-29
JP2012516349A (ja) 2012-07-19
EP2391616B1 (en) 2016-03-30
BRPI1007287B1 (pt) 2021-03-09
KR101693061B1 (ko) 2017-01-04
JP5658688B2 (ja) 2015-01-28
WO2010088392A1 (en) 2010-08-05
MX2011007639A (es) 2011-09-15
AU2010208247A1 (en) 2011-08-11
EA022083B1 (ru) 2015-10-30
UA106600C2 (uk) 2014-09-25
US8846600B2 (en) 2014-09-30
AU2010208247B2 (en) 2015-06-18
US20100190802A1 (en) 2010-07-29
BRPI1007287B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
JP5658688B2 (ja) カルボキサミド化合物およびその使用方法
EP2598483B1 (en) Ampk-activating heterocyclic compounds and methods for using the same
JP5650404B2 (ja) N−置換−ヘテロシクロアルキルオキシベンズアミド化合物およびその使用方法
EP2276761B1 (en) Carboxamide compounds for the treatment of metabolic disorders
EP2231666B1 (en) Carboxamide, sulfonamide and amine compounds for metabolic disorders
EA019509B1 (ru) Карбоксамидные, сульфонамидные и аминовые соединения от метаболических нарушений
WO2011123681A1 (en) Methods for using carboxamide, sulfonamide and amine compounds
WO2015048547A2 (en) Methods for using and biomarkers for ampk-activating compounds
EP3500558B1 (en) Benzimidazole direct ampk activators
WO2024263785A1 (en) Combination therapies of fasn inhibitors with thyroid hormone receptor agonists
HK1164860B (en) Carboxamide compounds and methods for using the same
HK1152939B (en) Carboxamide compounds for the treatment of metabolic disorders
HK1148525B (en) Carboxamide, sulfonamide and amine compounds for metabolic disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140924

CF01 Termination of patent right due to non-payment of annual fee